Vaccine Code Set Release Notes 3/14/2022

["Centers for Disease Control and Prevention" <no-reply@xxxxxxxxxxxxxxxxxxxx>]

Vaccine Code Set Update

If this is a forwarded email, Subscribe now to receive updates on this topic.

 

You are subscribed to one or more CDC code set page subscription services. Subscription links are available on each of the pages below.

• https://www2.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx
• https://www2.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=vg
• https://www2.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=mvx
• https://www2.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=tradename
• https://www2.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=ndc
• https://www2.cdc.gov/vaccines/iis/iisstandards/ndc_tableaccess.asp
• https://www2.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cpt
• https://www2.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvxvis
• https://www2a.cdc.gov/vaccines/iis/iisstandards/ndc_tableaccess.asp
• https://www.cdc.gov/vaccines/programs/iis/code-sets/vis-barcode-lookup-table.html
• https://www.cdc.gov/vaccines/programs/iis/code-sets/vis-url-table.html

 

Vaccine Code Set Update Publication Date:  March 14, 2022
The individual filenames included in this distribution contain the publication date (20220314)

 

Release Notes:  This release includes updates for all vaccine codes except core Vaccine Information Statement (VIS) codes.  In addition, the COVID-19 US Vaccine Codes table has been updated to reflect changes in this release. IIS COVID-19 Vaccine Related Code | CDC

 
Release notes are designed as a guide to highlight changes that have been made to the vaccine codes since the last publication.  They should not be used as the primary source of code information.  The vaccine code files themselves should be utilized.

 
General Note Regarding This Release:  Codes with “Last Update” dates from February 15, 2022 through March 14, 2022 reflect the changes and additions in this release.  

 
This release includes the following code set updates:
 

Vaccine Code Set Updates Not Related to COVID-19

• Tick-borne encephalitis (TBE) CVX codes
• CPT to CVX correction for DTaP vaccine
• Southern Hemisphere influenza codes added for 2022 season

COVID-19 Related Code Updates

1. Moderna vaccine code CPT to CVX added
2. Novavax vaccine codes reactivated
3. Sanofi Pasteur vaccine CVX codes added

Vaccine Code Set Updates Not Related to COVID-19

1. Tick-Borne Encephalitis (TBE) CVX codes

Correction: In a previous release, CVX code 77 was changed from Non-US status to active status and NDCs for the Pfizer adult TicoVac vaccine and associated CPT code were mapped to CVX 77.  This created downstream data issues.  This has now been corrected.  CVX code 77 is reset to be a Non-US Vaccine and all maps removed.  NDC and CPT codes for adult dose TicoVac are now mapped to new CVX code 224 (*). 
 

A new CVX code has been added for the pediatric TBE vaccine (223).  The Pfizer pediatric TicoVac vaccine has been FDA approved and is expected later in 2022 (there are currently no NDCs in the code set for this vaccine). 
 

Finally, a new unspecified CVX code 222 has been added.
 

All codes listed below are associated to the vaccine group Tick-borne encephalitis.
 

Table 1:  New Tick-Borne Encephalitis CVX Codes

CVX Code	CVX Description	CVX Short Description	Vaccine Status	Note
77	Tick-borne encephalitis vaccine (non-US)	Tick-borne encephalitis vaccine (non-US)	Non-US	Non-US vaccine
222	Tick-borne encephalitis vaccine, unspecified	Tick-borne encephalitis, unspecified	Inactive	Unspecified Code - should only be used when specific vaccine administered is unknown
223	Tick-borne encephalitis vaccine, inactivated, preservative free, 0.25mL dose	Tick-borne encephalitis, inactivated, PF, 0.25mL	Active	Pediatric dose vaccine
224	Tick-borne encephalitis vaccine, inactivated, preservative free, 0.5mL dose	Tick-borne encephalitis, inactivated, PF, 0.5mL	Active	Adult dose vaccine

(*) TicoVac adult vaccine related codes are now associated to CVX 224:  NDCs UoS 0069-0411-02/NDC UoU 0069-0411-01; CPT code 90627

2. CPT to CVX map correction for DTaP vaccine
   • Removed Map:  CPT Code 90700 “Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use” previously mapped to CVX Code 107 “diphtheria, tetanus toxoids and acellular pertussis vaccine, unspecified formulation”
   • Added Map:  CPT Code 90700 “Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use” now mapped to CVX Code 20 “diphtheria, tetanus toxoids and acellular pertussis vaccine”

 

3. Southern Hemisphere Influenza Season 2022 Vaccines

The following new NDCs have been added and mapped.

 
Table 2:  Southern Hemisphere Influenza 2022

Southern Hemisphere 2022 Influenza Season
CVX Code	CVX Short Description	Sale Proprietary Name	Sale Labeler	MVX Code	Unit of Sale NDC11	Unit of Use NDC11	Presentation
201	influenza, Southern Hemisphere, preservative free	FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE	Sanofi Pasteur Inc.	PMC	49281-0322-50	49281-0322-88	SYRINGE, 0.5 mL
202	influenza, Southern Hemisphere, quadrivalent, with preservative	FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE	Sanofi Pasteur Inc.	PMC	49281-0339-15	49281-0339-78	VIAL, MULTI-DOSE, 5 mL

COVID-19 Related Code Updates

COVID-19 vaccine codes and crosswalks are provided in anticipation of potential vaccine availability under an approved Biologics License Application (BLA), Emergency Use Authorization (EUA), or as a potential vaccine submission for EUA (Pre-EUA).  Codes will become effective for US vaccine administrations only upon EUA issuance and/or BLA approval of COVID-19 vaccine(s) by the FDA.  All CVX codes are associated to the new Vaccine Group “COVID-19."  CPT codes shown are product codes.  CPT administrative codes for doses are available on the AMA website.  CPT product codes are added as the AMA approves and makes them available.

1. Moderna COVID-19 Vaccine Code Updated:  2.5 mL vial 50 mcg/0.50 mL for booster only, adult 18+ (Pre-EUA, FDA EUA authorization pending)
   • CPT to CVX Code Map Added:  CPT Code 91309 “Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use” mapped to CVX Code 221 “SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose”
2. Novavax COVID-19 Vaccine Codes Reactivated:  Adult primary series (Pre-EUA, FDA EUA authorization pending)

Table 3:  NDCs and associated codes reactivated or reassociated for the Novavax COVID-19 Vaccine

Unit of Sale	Unit of Use	CVX	MVX	CPT
80631-100-10	80631-100-01	211	NVX	91304

3. Sanofi Pasteur COVID-19 Vaccine – New Codes (Pre-EUA, FDA EUA Authorization pending)
   Sanofi Pasteur is in process of an FDA EUA submission for two presentations; an adult primary series vaccine, and a separate booster dose vaccine.  Sanofi currently does not have plans to manufacture and distribute the primary series dose initially, thus the CVX code status for that presentation has been set to Pending.  Sanofi plans to produce the booster dose when and if it is authorized under EUA.  NDCs and CPT codes are not yet available or included in this code set release.

Table 4:  New CVX Codes associated to Sanofi Pasteur COVID-19 Vaccine – No NDCs or CPT codes available 

CVX Code	CVX Description	CVX Short Description	Vaccine Status	Note
226	SARS-COV-2 (COVID-19) vaccine, D614, prefusion spike recombinant protein subunit (CoV2 preS dTM), AS03 adjuvant added, preservative free, 10mcg/0.5mL dose	COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL	Pending	Pre-EUA Authorization, Sanofi Primary Series dose - requires addition of AS03 adjuvant
225	SARS-COV-2 (COVID-19) vaccine, D614, prefusion spike recombinant protein subunit (CoV2 preS dTM), AS03 adjuvant added, preservative free, 5mcg/0.5mL dose	COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL	Active	Pre-EUA Authorization, Sanofi Booster dose - requires addition of AS03 adjuvant